MannKind (NasdaqGM:MNKD) 2025 Conference November 19, 2025 06:30 AM ET Company ParticipantsMichael Castagna - CEOMichael CastagnaWhich insulin and IU patient will get? Insulin and IU patient will get. I'll talk about in a second. We've initiated a IB trial here for nintedanib. That'll be mainly in the U.S. to satisfy the FDA to go into phase III. We have INFLOW 2, which will be going out ex-U.S., and that will be the bridge to the phase III dosing. I'll start off with the newest acquisitions, and that's whe ...